Erlotinib

Name: Erlotinib | 183321-74-6
Brand: US-CATO
SKU: S57C4X-1069123_25_MG
Price: 19998.0 USD
Availability: InStock

Cat. No S57C4X-1069123_25_MG

Vendor: US-CATO

Product Information

Product Name

Erlotinib

Brand Name

US-CATO

Product Number

C4X-1069123

CAS

183321-74-6

Certificate of Analysis (COA)

COA not found

General Information

PubChem CID

176870

IUPAC Name

N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine

InChI Key

AAKJLRGGTJKAMG-UHFFFAOYSA-N

SMILES

COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC

References Data Source From Pubchem

Correction: The − 216G/T polymorphism in the EGFR gene: a review focusing on non-small cell lung cancer

Publication Name: Molecular Biology Reports

Publication Date: 2026-06-03

DOI: 10.1007/s11033-025-11242-3|10.1007/s11033-026-11952-2

Correction: Magnolin overcomes EGFR TKI resistance in NSCLC by modulation of NDRG1–NRG2–HECW1 pathway

Publication Name: Acta Pharmacologica Sinica

Publication Date: 2026-05-18

DOI: 10.1038/s41401-025-01670-z|10.1038/s41401-026-01837-2

Advancing Rare Cancer Therapeutics: Osimertinib-Loaded Inhaled PLGA Nanoparticles for Mesothelioma Treatment

Publication Name: AAPS PharmSciTech

Publication Date: 2026-03-04

DOI: 10.1208/s12249-025-03322-1

Reinforcement learning-based design of sequential drug treatment targeting the evolving tumour landscape with SequenTx

Publication Name: Nature Machine Intelligence

Publication Date: 2026-03-04

DOI: 10.1038/s42256-026-01192-1

Harnessing mitophagy for melanoma: enhancing prognosis through immune activation

Publication Name: Archives of Dermatological Research

Publication Date: 2026-03-02

DOI: 10.1007/s00403-026-04567-x

Erlotinib

Product Information

General Information

References Data Source From Pubchem

Correction: The − 216G/T polymorphism in the EGFR gene: a review focusing on non-small cell lung cancer

Correction: Magnolin overcomes EGFR TKI resistance in NSCLC by modulation of NDRG1–NRG2–HECW1 pathway

Advancing Rare Cancer Therapeutics: Osimertinib-Loaded Inhaled PLGA Nanoparticles for Mesothelioma Treatment

Reinforcement learning-based design of sequential drug treatment targeting the evolving tumour landscape with SequenTx

Harnessing mitophagy for melanoma: enhancing prognosis through immune activation

Erlotinib

Mycophenolate Mofetil EP Impurity H

Mycophenolate Mofetil

Flurbiprofen Impurity 21 (Mixture of Diastereomers)

Docetaxel Impurity 40

H-Met-Glu-OH

Fluticasone Impurity 106

Efavirenz Related Compound C

Cholecalciferol EP Impurity A

About Us

Popular Searches

Contact

#title#

Features
Availability:
Price
Options
Actions

Erlotinib

Product Information

General Information

References Data Source From Pubchem

Correction: The − 216G/T polymorphism in the EGFR gene: a review focusing on non-small cell lung cancer

Correction: Magnolin overcomes EGFR TKI resistance in NSCLC by modulation of NDRG1–NRG2–HECW1 pathway

Advancing Rare Cancer Therapeutics: Osimertinib-Loaded Inhaled PLGA Nanoparticles for Mesothelioma Treatment

Reinforcement learning-based design of sequential drug treatment targeting the evolving tumour landscape with SequenTx

Harnessing mitophagy for melanoma: enhancing prognosis through immune activation

Erlotinib

Related Product

Mycophenolate Mofetil EP Impurity H

Mycophenolate Mofetil

Flurbiprofen Impurity 21 (Mixture of Diastereomers)

Docetaxel Impurity 40

H-Met-Glu-OH

Fluticasone Impurity 106

Efavirenz Related Compound C

Cholecalciferol EP Impurity A

#title#

Login

Register